The present invention generally relates to the field of
genome engineering (
gene editing), and more specifically to
ex vivo gene therapy for the treatment of Activated PI3
kinase Delta Syndrome type 1 (
APDS1) related to PIK3CD
gene. Particularly, the present invention pertains to the treatment of PIK3CD deficiency in hematopoietic stem cells (HSCs) and / or T-cells. The present invention provides means and methods for genetically modifying HSCs and / or T-cells involving gene editing reagents, such as TALE-nucleases, that specifically target an endogenous PIK3CD locus, at least in the PIK3CD
allele comprising at least one
APDS1-associated
mutation, thereby allowing the restoration of the normal
cellular phenotype. The present invention also provides engineered PIK3CD-edited HSCs and engineered PIK3CD-edited T-cells comprising at least one exogenous sequence comprising a
nucleic acid sequence encoding a functional PI3Kδ
protein which is integrated in said HSCs' or T-cells'
genome into a PIK3CD locus, in a non-functional PIK3CD
allele, resulting in the expression of a functional PI3Kδ polypeptide. The present invention further provides populations of cells comprising said engineered HSCs or T-cells, pharmaceutical compositions comprising said engineered cells or populations of cells, as well as their use in gene therapy for the treatment of
APDS1.